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The emergence of severe acute respiratory syndrome 
coronavirus (SARS-CoV) and Middle East respiratory 
syndrome (MERS)-CoV underscores the threat of cross-species 
transmission events leading to outbreaks in humans. Here we 
examine the disease potential of a SARS-like virus, SHC014-
CoV, which is currently circulating in Chinese horseshoe bat 
populations1. Using the SARS-CoV reverse genetics system2, 
we generated and characterized a chimeric virus expressing 
the spike of bat coronavirus SHC014 in a mouse-adapted 
SARS-CoV backbone. The results indicate that group 2b 
viruses encoding the SHC014 spike in a wild-type backbone 
can efficiently use multiple orthologs of the SARS receptor 
human angiotensin converting enzyme II (ACE2), replicate 
efficiently in primary human airway cells and achieve in vitro 
titers equivalent to epidemic strains of SARS-CoV. Additionally, 
in vivo experiments demonstrate replication of the chimeric 
virus in mouse lung with notable pathogenesis. Evaluation of 
available SARS-based immune-therapeutic and prophylactic 
modalities revealed poor efficacy; both monoclonal antibody 
and vaccine approaches failed to neutralize and protect from 
infection with CoVs using the novel spike protein. On the basis 
of these findings, we synthetically re-derived an infectious 
full-length SHC014 recombinant virus and demonstrate robust 
viral replication both in vitro and in vivo. Our work suggests a 
potential risk of SARS-CoV re-emergence from viruses currently 
circulating in bat populations.
The emergence of SARS-CoV heralded a new era in the cross-species 
transmission of severe respiratory illness with globalization leading to 
rapid spread around the world and massive economic impact3,4. Since 
then, several strains—including influenza A strains H5N1, H1N1 and 
H7N9 and MERS-CoV—have emerged from animal populations, 
causing considerable disease, mortality and economic hardship for 
the afflicted regions5. Although public health measures were able to 
stop the SARS-CoV outbreak4, recent metagenomics studies have 
identified sequences of closely related SARS-like viruses circulating 
in Chinese bat populations that may pose a future threat1,6. However, 
sequence data alone provides minimal insights to identify and prepare 
for future prepandemic viruses. Therefore, to examine the emergence 
potential (that is, the potential to infect humans) of circulating bat 
CoVs, we built a chimeric virus encoding a novel, zoonotic CoV spike 
protein—from the RsSHC014-CoV sequence that was isolated from 
Chinese horseshoe bats1—in the context of the SARS-CoV mouse-
adapted backbone. The hybrid virus allowed us to evaluate the ability 
of the novel spike protein to cause disease independently of other 
necessary adaptive mutations in its natural backbone. Using this 
approach, we characterized CoV infection mediated by the SHC014 
spike protein in primary human airway cells and in vivo, and tested 
the efficacy of available immune therapeutics against SHC014-CoV. 
Together, the strategy translates metagenomics data to help predict 
and prepare for future emergent viruses.
The sequences of SHC014 and the related RsWIV1-CoV show that 
these CoVs are the closest relatives to the epidemic SARS-CoV strains 
(Fig. 1a,b); however, there are important differences in the 14 resi-
dues that bind human ACE2, the receptor for SARS-CoV, including 
the five that are critical for host range: Y442, L472, N479, T487 and 
Y491 (ref. 7). In WIV1, three of these residues vary from the epidemic 
SARS-CoV Urbani strain, but they were not expected to alter binding 
to ACE2 (Supplementary Fig. 1a,b and Supplementary Table 1). 
This fact is confirmed by both pseudotyping experiments that meas-
ured the ability of lentiviruses encoding WIV1 spike proteins to enter 
cells expressing human ACE2 (Supplementary Fig. 1) and by in vitro 
replication assays of WIV1-CoV (ref. 1). In contrast, 7 of 14 ACE2-
interaction residues in SHC014 are different from those in SARS-CoV, 
including all five residues critical for host range (Supplementary 
Fig. 1c and Supplementary Table 1). These changes, coupled with 
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the failure of pseudotyped lentiviruses expressing the SHC014 spike 
to enter cells (Supplementary Fig. 1d), suggested that the SHC014 
spike is unable to bind human ACE2. However, similar changes in 
related SARS-CoV strains had been reported to allow ACE2 bind-
ing7,8, suggesting that additional functional testing was required for 
verification. Therefore, we synthesized the SHC014 spike in the con-
text of the replication-competent, mouse-adapted SARS-CoV back-
bone (we hereafter refer to the chimeric CoV as SHC014-MA15) to 
maximize the opportunity for pathogenesis and vaccine studies in 
mice (Supplementary Fig. 2a). Despite predictions from both struc-
ture-based modeling and pseudotyping experiments, SHC014-MA15 
was viable and replicated to high titers in Vero cells (Supplementary 
Fig. 2b). Similarly to SARS, SHC014-MA15 also required a func-
tional ACE2 molecule for entry and could use human, civet and bat 
ACE2 orthologs (Supplementary Fig. 2c,d). To test the ability of the 
SHC014 spike to mediate infection of the human airway, we examined 
the sensitivity of the human epithelial airway cell line Calu-3 2B4 (ref. 
9) to infection and found robust SHC014-MA15 replication, compa-
rable to that of SARS-CoV Urbani (Fig. 1c). To extend these findings, 
primary human airway epithelial (HAE) cultures were infected and 
showed robust replication of both viruses (Fig. 1d). Together, the 
data confirm the ability of viruses with the SHC014 spike to infect 
human airway cells and underscore the potential threat of cross-spe-
cies transmission of SHC014-CoV.
To evaluate the role of the SHC014 spike in mediating infection 
in vivo, we infected 10-week-old BALB/c mice with 104 plaque- 
forming units (p.f.u.) of either SARS-MA15 or SHC014-MA15 
(Fig. 1e–h). Animals infected with SARS-MA15 experienced rapid 
weight loss and lethality by 4 d post infection (d.p.i.); in contrast, 
SHC014-MA15 infection produced substantial weight loss (10%) 
but no lethality in mice (Fig. 1e). Examination of viral replica-
tion revealed nearly equivalent viral titers from the lungs of mice 
infected with SARS-MA15 or SHC014-MA15 (Fig. 1f). Whereas 
lungs from the SARS-MA15–infected mice showed robust staining 
in both the terminal bronchioles and the lung parenchyma 2 d.p.i. 
(Fig. 1g), those of SHC014-MA15–infected mice showed reduced 
airway antigen staining (Fig. 1h); in contrast, no deficit in antigen 
staining was observed in the parenchyma or in the overall histology 
scoring, suggesting differential infection of lung tissue for SHC014-
MA15 (Supplementary Table 2). We next analyzed infection in 
more susceptible, aged (12-month-old) animals. SARS-MA15–
infected animals rapidly lost weight and succumbed to infection 
(Supplementary Fig. 3a,b). SHC014-MA15 infection induced robust 
and sustained weight loss, but had minimal lethality. Trends in the 
histology and antigen staining patterns that we observed in young 
mice were conserved in the older animals (Supplementary Table 3). 
We excluded the possibility that SHC014-MA15 was mediating 
infection through an alternative receptor on the basis of experiments 
using Ace2−/− mice, which did not show weight loss or antigen stain-
ing after SHC014-MA15 infection (Supplementary Fig. 4a,b and 
Supplementary Table 2). Together, the data indicate that viruses with 
the SHC014 spike are capable of inducing weight loss in mice in the 
context of a virulent CoV backbone.
Given the preclinical efficacy of Ebola monoclonal antibody 
therapies, such as ZMApp10, we next sought to determine the 
efficacy of SARS-CoV monoclonal antibodies against infection with 
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Figure 1 SARS-like viruses replicate in human airway cells and  
produce in vivo pathogenesis. (a) The full-length genome sequences  
of representative CoVs were aligned and phylogenetically mapped as  
described in the Online Methods. The scale bar represents nucleotide  
substitutions, with only bootstrap support above 70% being labeled.  
The tree shows CoVs divided into three distinct phylogenetic groups,  
defined as α-CoVs, β-CoVs and γ-CoVs. Classical subgroup clusters are  
marked as 2a, 2b, 2c and 2d for the β-CoVs and as 1a and 1b for the  
α-CoVs. (b) Amino acid sequences of the S1 domains of the spikes of  
representative β-CoVs of the 2b group, including SARS-CoV, were  
aligned and phylogenetically mapped. The scale bar represents amino  
acid substitutions. (c,d) Viral replication of SARS-CoV Urbani (black)  
and SHC014-MA15 (green) after infection of Calu-3 2B4 cells (c) or  
well-differentiated, primary air-liquid interface HAE cell cultures (d)  
at a multiplicity of infection (MOI) of 0.01 for both cell types. Samples  
were collected at individual time points with biological replicates (n = 3)  
for both Calu-3 and HAE experiments. (e,f) Weight loss (n = 9 for  
SARS-CoV MA15; n = 16 for SHC014-MA15) (e) and viral replication  
in the lungs (n = 3 for SARS-CoV MA15; n = 4 for SHC014-MA15) (f)  
of 10-week-old BALB/c mice infected with 1 × 104 p.f.u. of mouse- 
adapted SARS-CoV MA15 (black) or SHC014-MA15 (green) via the intranasal (i.n.) route. (g,h) Representative images of lung sections stained for 
SARS-CoV N antigen from mice infected with SARS-CoV MA15 (n = 3 mice) (g) or SHC014-MA15 (n = 4 mice) (h) are shown. For each graph, the 
center value represents the group mean, and the error bars define the s.e.m. Scale bars, 1 mm.
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SHC014-MA15. Four broadly neutralizing 
human monoclonal antibodies targeting 
SARS-CoV spike protein had been previously 
reported and are probable reagents for immu-
notherapy11–13. We examined the effect of 
these antibodies on viral replication (expressed as percentage inhibi-
tion of viral replication) and found that whereas wild-type SARS-CoV 
Urbani was strongly neutralized by all four antibodies at relatively 
low antibody concentrations (Fig. 2a–d), neutralization varied for 
SHC014-MA15. Fm6, an antibody generated by phage display and 
escape mutants11,12, achieved only background levels of inhibition 
of SHC014-MA15 replication (Fig. 2a). Similarly, antibodies 230.15 
and 227.14, which were derived from memory B cells of SARS-CoV–
infected patients13, also failed to block SHC014-MA15 replication 
(Fig. 2b,c). For all three antibodies, differences between the SARS 
and SHC014 spike amino acid sequences corresponded to direct or 
adjacent residue changes found in SARS-CoV escape mutants (fm6 
N479R; 230.15 L443V; 227.14 K390Q/E), which probably explains 
the absence of the antibodies’ neutralizing activity against SHC014. 
Finally, monoclonal antibody 109.8 was able to achieve 50% neutrali-
zation of SHC014-MA15, but only at high concentrations (10 µg/ml) 
(Fig. 2d). Together, the results demonstrate that broadly neutralizing 
antibodies against SARS-CoV may only have marginal efficacy against 
emergent SARS-like CoV strains such as SHC014.
To evaluate the efficacy of existing vaccines against infection with 
SHC014-MA15, we vaccinated aged mice with double-inactivated 
whole SARS-CoV (DIV). Previous work showed that DIV could 
neutralize and protect young mice from challenge with a homolo-
gous virus14; however, the vaccine failed to protect aged animals in 
which augmented immune pathology was also observed, indicating 
the possibility of the animals being harmed because of the vaccina-
tion15. Here we found that DIV did not provide protection from chal-
lenge with SHC014-MA15 with regards to weight loss or viral titer 
(Supplementary Fig. 5a,b). Consistent with a previous report with 
other heterologous group 2b CoVs15, serum from DIV-vaccinated, 
aged mice also failed to neutralize SHC014-MA15 (Supplementary 
Fig. 5c). Notably, DIV vaccination resulted in robust immune pathol-
ogy (Supplementary Table 4) and eosinophilia (Supplementary 
Fig. 5d–f). Together, these results confirm that the DIV vaccine would 
not be protective against infection with SHC014 and could possibly 
augment disease in the aged vaccinated group.
In contrast to vaccination of mice with DIV, the use of SHC014-
MA15 as a live, attenuated vaccine showed potential cross-protec-
tion against challenge with SARS-CoV, but the results have important 
caveats. We infected young mice with 104 p.f.u. of SHC014-MA15 and 
observed them for 28 d. We then challenged the mice with SARS-
MA15 at day 29 (Supplementary Fig. 6a). The prior infection of 
the mice with the high dose of SHC014-MA15 conferred protection 
against challenge with a lethal dose of SARS-MA15, although there 
was only a minimal SARS-CoV neutralization response from the 
antisera elicited 28 d after SHC014-MA15 infection (Supplementary 
Fig. 6b, 1:200). In the absence of a secondary antigen boost, 28 d.p.i. 
represents the expected peak of antibody titers and implies that there 
will be diminished protection against SARS-CoV over time16,17. 
Similar results showing protection against challenge with a lethal dose 
of SARS-CoV were observed in aged BALB/c mice with respect to 
weight loss and viral replication (Supplementary Fig. 6c,d). However, 
the SHC014-MA15 infection dose of 104 p.f.u. induced >10% weight 
loss and lethality in some aged animals (Fig. 1 and Supplementary 
Fig. 3). We found that vaccination with a lower dose of SHC014-MA15 
(100 p.f.u.), did not induce weight loss, but it also failed to protect aged 
animals from a SARS-MA15 lethal dose challenge (Supplementary 
Fig. 6e,f). Together, the data suggest that SHC014-MA15 challenge 
may confer cross-protection against SARS-CoV through conserved 
epitopes, but the required dose induces pathogenesis and precludes 
use as an attenuated vaccine.
Having established that the SHC014 spike has the ability to 
mediate infection of human cells and cause disease in mice, we next 
synthesized a full-length SHC014-CoV infectious clone based on the 
approach used for SARS-CoV (Fig. 3a)2. Replication in Vero cells 
revealed no deficit for SHC014-CoV relative to that for SARS-CoV 
(Fig. 3b); however, SHC014-CoV was significantly (P < 0.01) attenu-
ated in primary HAE cultures at both 24 and 48 h after infection 
(Fig. 3c). In vivo infection of mice demonstrated no significant 
weight loss but showed reduced viral replication in lungs of full-
length SHC014-CoV infection, as compared to SARS-CoV Urbani 
(Fig. 3d,e). Together, the results establish the viability of full-length 
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Figure 2 SARS-CoV monoclonal antibodies 
have marginal efficacy against SARS-like CoVs. 
(a–d) Neutralization assays evaluating efficacy 
(measured as reduction in the number of 
plaques) of a panel of monoclonal antibodies, 
which were all originally generated against 
epidemic SARS-CoV, against infection of 
Vero cells with SARS-CoV Urbani (black) or 
SHC014-MA15 (green). The antibodies tested 
were fm6 (n = 3 for Urbani; n = 5 for SHC014-
MA15)11,12 (a), 230.15 (n = 3 for Urbani;  
n = 2 for SHC014-MA15) (b), 227.15 (n = 3 for 
Urbani; n = 5 for SHC014-MA15) (c) and 109.8 
(n = 3 for Urbani; n = 2 for SHC014-MA15)13 (d). 
Each data point represents the group mean  
and error bars define the s.e.m. Note that the 
error bars in SARS-CoV Urbani–infected Vero 
cells in b,c are overlapped by the symbols and 
are not visible.
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SHC014-CoV, but suggest that further adaptation is required for its 
replication to be equivalent to that of epidemic SARS-CoV in human 
respiratory cells and in mice.
During the SARS-CoV epidemic, links were quickly established 
between palm civets and the CoV strains that were detected in 
humans4. Building on this finding, the common emergence paradigm 
argues that epidemic SARS-CoV originated as a bat virus, jumped to 
civets and incorporated changes within the receptor-binding domain 
(RBD) to improve binding to civet Ace2 (ref. 18). Subsequent expo-
sure to people in live-animal markets permitted human infection with 
the civet strain, which, in turn, adapted to become the epidemic strain 
(Fig. 4a). However, phylogenetic analysis suggests that early human 
SARS strains appear more closely related to bat strains than to civet 
strains18. Therefore, a second paradigm argues that direct bat-human 
transmission initiated SARS-CoV emergence and that palm civets 
served as a secondary host and reservoir for continued infection 
(Fig. 4b)19. For both paradigms, spike adaptation in a secondary host 
is seen as a necessity, with most mutations expected to occur within 
the RBD, thereby facilitating improved infection. Both theories imply 
that pools of bat CoVs are limited and that host-range mutations are 
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Figure 4 Emergence paradigms for 
coronaviruses. Coronavirus strains are 
maintained in quasi-species pools circulating  
in bat populations. (a,b) Traditional  
SARS-CoV emergence theories posit that host- 
range mutants (red circle) represent random  
and rare occurrences that permit infection  
of alternative hosts. The secondary-host 
paradigm (a) argues that a nonhuman host is 
infected by a bat progenitor virus and,  
through adaptation, facilitates transmission 
to humans; subsequent replication in humans 
leads to the epidemic viral strain. The direct 
paradigm (b) suggests that transmission 
occurs between bats and humans without the 
requirement of an intermediate host; selection 
then occurs in the human population with 
closely related viruses replicating in a secondary 
host, permitting continued viral persistence and 
adaptation in both. (c) The data from chimeric 
SARS-like viruses argue that the quasi-species 
pools maintain multiple viruses capable of 
infecting human cells without the need for 
mutations (red circles). Although adaptations in 
secondary or human hosts may be required for 
epidemic emergence, if SHC014 spike–containing viruses recombined with virulent CoV backbones (circles with green outlines), then epidemic disease 
may be the result in humans. Existing data support elements of all three paradigms.
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Figure 3 Full-length SHC014-CoV replicates in human airways but  
lacks the virulence of epidemic SARS-CoV. (a) Schematic of the  
SHC014-CoV molecular clone, which was synthesized as six  
contiguous cDNAs (designated SHC014A, SHC014B, SHC014C,  
SHC014D, SHC014E and SHC014F) flanked by unique BglI sites  
that allowed for directed assembly of the full-length cDNA expressing  
open reading frames (for 1a, 1b, spike, 3, envelope, matrix, 6–8 and  
nucleocapsid). Underlined nucleotides represent the overhang  
sequences formed after restriction enzyme cleavage. (b,c) Viral  
replication of SARS-CoV Urbani (black) or SHC014-CoV (green) after  
infection of Vero cells (b) or well-differentiated, primary air-liquid interface HAE cell cultures (c) at an MOI of 0.01. Samples were collected at 
individual time points with biological replicates (n = 3) for each group. Data represent one experiment for both Vero and HAE cells. (d,e) Weight loss  
(n = 3 for SARS-CoV MA15, n = 7 for SHC014-CoV; n = 6 for SARS-Urbani) (d) and viral replication in the lungs (n = 3 for SARS-Urbani and  
SHC014-CoV) (e) of 10-week-old BALB/c mice infected with 1 × 105 p.f.u. of SARS-CoV MA15 (gray), SHC014-CoV (green) or SARS-CoV Urbani 
(black) via the i.n. route. Each data point represents the group mean, and error bars define the s.e.m. **P < 0.01 and ***P < 0.001 using two-tailed 
Student’s t-test of individual time points. 
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both random and rare, reducing the likelihood of future emergence 
events in humans.
Although our study does not invalidate the other emergence routes, 
it does argue for a third paradigm in which circulating bat CoV 
pools maintain ‘poised’ spike proteins that are capable of infecting 
humans without mutation or adaptation (Fig. 4c). This hypothesis is 
illustrated by the ability of a chimeric virus containing the SHC014 
spike in a SARS-CoV backbone to cause robust infection in both 
human airway cultures and in mice without RBD adaptation. Coupled 
with the observation of previously identified pathogenic CoV back-
bones3,20, our results suggest that the starting materials required 
for SARS-like emergent strains are currently circulating in animal 
reservoirs. Notably, although full-length SHC014-CoV probably 
requires additional backbone adaption to mediate human disease, the 
documented high-frequency recombination events in CoV families 
underscores the possibility of future emergence and the need for 
further preparation.
To date, genomics screens of animal populations have prima-
rily been used to identify novel viruses in outbreak settings21. The 
approach here extends these data sets to examine questions of viral 
emergence and therapeutic efficacy. We consider viruses with the 
SHC014 spike a potential threat owing to their ability to replicate in 
primary human airway cultures, the best available model for human 
disease. In addition, the observed pathogenesis in mice indicates a 
capacity for SHC014-containing viruses to cause disease in mamma-
lian models, without RBD adaptation. Notably, differential tropism 
in the lung as compared to that with SARS-MA15 and attenuation 
of full-length SHC014-CoV in HAE cultures relative to SARS-CoV 
Urbani suggest that factors beyond ACE2 binding—including spike 
processivity, receptor bio-availability or antagonism of the host 
immune responses—may contribute to emergence. However, further 
testing in nonhuman primates is required to translate these finding 
into pathogenic potential in humans. Importantly, the failure of 
available therapeutics defines a critical need for further study and 
for the development of treatments. With this knowledge, surveil-
lance programs, diagnostic reagents and effective treatments can 
be produced that are protective against the emergence of group 
2b–specific CoVs, such as SHC014, and these can be applied to other 
CoV branches that maintain similarly heterogeneous pools.
In addition to offering preparation against future emerging 
viruses, this approach must be considered in the context of the 
US government–mandated pause on gain-of-function (GOF) 
studies22. On the basis of previous models of emergence (Fig. 4a,b), 
the creation of chimeric viruses such as SHC014-MA15 was not 
expected to increase pathogenicity. Although SHC014-MA15 is 
attenuated relative to its parental mouse-adapted SARS-CoV, simi-
lar studies examining the pathogenicity of CoVs with the wild-type 
Urbani spike within the MA15 backbone showed no weight loss in 
mice and reduced viral replication23. Thus, relative to the Urbani 
spike–MA15 CoV, SHC014-MA15 shows a gain in pathogenesis 
(Fig. 1). On the basis of these findings, scientific review panels may 
deem similar studies building chimeric viruses based on circulating 
strains too risky to pursue, as increased pathogenicity in mammalian 
models cannot be excluded. Coupled with restrictions on mouse-
adapted strains and the development of monoclonal antibodies using 
escape mutants, research into CoV emergence and therapeutic effi-
cacy may be severely limited moving forward. Together, these data 
and restrictions represent a crossroads of GOF research concerns; 
the potential to prepare for and mitigate future outbreaks must be 
weighed against the risk of creating more dangerous pathogens. 
In developing policies moving forward, it is important to consider 
the value of the data generated by these studies and whether these 
types of chimeric virus studies warrant further investigation versus 
the inherent risks involved.
Overall, our approach has used metagenomics data to identify a 
potential threat posed by the circulating bat SARS-like CoV SHC014. 
Because of the ability of chimeric SHC014 viruses to replicate in 
human airway cultures, cause pathogenesis in vivo and escape cur-
rent therapeutics, there is a need for both surveillance and improved 
therapeutics against circulating SARS-like viruses. Our approach also 
unlocks the use of metagenomics data to predict viral emergence and 
to apply this knowledge in preparing to treat future emerging virus 
infections.
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ONLINE METHOdS
Viruses, cells, in vitro infection and plaque assays. Wild-type SARS-CoV 
(Urbani), mouse-adapted SARS-CoV (MA15) and chimeric SARS-like CoVs 
were cultured on Vero E6 cells (obtained from United States Army Medical 
Research Institute of Infectious Diseases), grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco, CA) and 5% fetal clone serum (FCS) (Hyclone, 
South Logan, UT) along with antibiotic/antimycotic (Gibco, Carlsbad, CA). 
DBT cells (Baric laboratory, source unknown) expressing ACE2 orthologs have 
been previously described for both human and civet; bat Ace2 sequence was 
based on that from Rhinolophus leschenaulti, and DBT cells expressing bat 
Ace2 were established as described previously8. Pseudotyping experiments 
were similar to those using an HIV-based pseudovirus, prepared as previously 
described10, and examined on HeLa cells (Wuhan Institute of Virology) that 
expressed ACE2 orthologs. HeLa cells were grown in minimal essential medium 
(MEM) (Gibco, CA) supplemented with 10% FCS (Gibco, CA) as previously 
described24. Growth curves in Vero E6, DBT, Calu-3 2B4 and primary human 
airway epithelial cells were performed as previously described8,25. None of the 
working cell line stocks were authenticated or tested for mycoplasma recently, 
although the original seed stocks used to create the working stocks are free from 
contamination. Human lungs for HAE cultures were procured under University 
of North Carolina at Chapel Hill Institutional Review Board–approved proto-
cols. HAE cultures represent highly differentiated human airway epithelium 
containing ciliated and non-ciliated epithelial cells as well as goblet cells. 
The cultures are also grown on an air-liquid interface for several weeks before 
use, as previously described26. Briefly, cells were washed with PBS and inocu-
lated with virus or mock-diluted in PBS for 40 min at 37 °C. After inoculation, 
cells were washed three times and fresh medium was added to signify time ‘0’. 
Three or more biological replicates were harvested at each described time point. 
No blinding was used in any sample collections nor were samples randomized. 
All virus cultivation was performed in a biosafety level (BSL) 3 laboratory with 
redundant fans in the biosafety cabinets, as described previously by our group2. 
All personnel wore powered air purifying respirators (Breathe Easy, 3M) with 
Tyvek suits, aprons and booties and were double-gloved.
Sequence clustering and structural modeling. The full-length genomic 
sequences and the amino acid sequences of the S1 domains of the spike of rep-
resentative CoVs were downloaded from Genbank or Pathosystems Resource 
Integration Center (PATRIC), aligned with ClustalX and phylogenetically 
compared by using maximum likelihood estimation using 100 bootstraps or 
by using the PhyML (https://code.google.com/p/phyml/) package, respectively. 
The tree was generated using maximum likelihood with the PhyML package. 
The scale bar represents nucleotide substitutions. Only nodes with bootstrap 
support above 70% are labeled. The tree shows that CoVs are divided into 
three distinct phylogenetic groups defined as α-CoVs, β-CoVs and γ-CoVs. 
Classical subgroup clusters are marked as 2a, 2b, 2c and 2d for β-CoVs, and 
1a and 1b for the α-CoVs. Structural models were generated using Modeller 
(Max Planck Institute Bioinformatics Toolkit) to generate homology models 
for SHC014 and Rs3367 of the SARS RBD in complex with ACE2 based on 
crystal structure 2AJF (Protein Data Bank). Homology models were visualized 
and manipulated in MacPyMol (version 1.3).
Construction of SARS-like chimeric viruses. Both wild-type and chimeric 
viruses were derived from either SARS-CoV Urbani or the correspond-
ing mouse-adapted (SARS-CoV MA15) infectious clone (ic) as previously 
described27. Plasmids containing spike sequences for SHC014 were extracted 
by restriction digest and ligated into the E and F plasmid of the MA15 infec-
tious clone. The clone was designed and purchased from Bio Basic as six 
contiguous cDNAs using published sequences flanked by unique class II 
restriction endonuclease sites (BglI). Thereafter, plasmids containing wild-
type, chimeric SARS-CoV and SHC014-CoV genome fragments were ampli-
fied, excised, ligated and purified. In vitro transcription reactions were then 
preformed to synthesize full-length genomic RNA, which was transfected into 
Vero E6 cells as previously described2. The medium from transfected cells was 
harvested and served as seed stocks for subsequent experiments. Chimeric and 
full-length viruses were confirmed by sequence analysis before use in these 
studies. Synthetic construction of chimeric mutant and full-length SHC014-
CoV was approved by the University of North Carolina Institutional Biosafety 
Committee and the Dual Use Research of Concern committee.
Ethics statement. This study was carried out in accordance with the recom-
mendations for the care and use of animals by the Office of Laboratory Animal 
Welfare (OLAW), NIH. The Institutional Animal Care and Use Committee 
(IACUC) of The University of North Carolina at Chapel Hill (UNC, Permit 
Number A-3410-01) approved the animal study protocol (IACUC #13-033) 
used in these studies.
Mice and in vivo infection. Female, 10-week-old and 12-month-old BALB/
cAnNHsD mice were ordered from Harlan Laboratories. Mouse infections 
were done as previously described20. Briefly, animals were brought into a 
BSL3 laboratory and allowed to acclimate for 1 week before infection. For 
infection and live-attenuated virus vaccination, mice were anesthetized with a 
mixture of ketamine and xylazine and infected intranasally, when challenged, 
with 50 µl of phosphate-buffered saline (PBS) or diluted virus with three or 
four mice per time point, per infection group per dose as described in the 
figure legends. For individual mice, notations for infection including failure 
to inhale the entire dose, bubbling of inoculum from the nose, or infection 
through the mouth may have led to exclusion of mouse data at the discre-
tion of the researcher; post-infection, no other pre-established exclusion or 
inclusion criteria are defined. No blinding was used in any animal experi-
ments, and animals were not randomized. For vaccination, young and aged 
mice were vaccinated by footpad injection with a 20-µl volume of either 0.2 µg 
of double-inactivated SARS-CoV vaccine with alum or mock PBS; mice 
were then boosted with the same regimen 22 d later and challenged 21 d 
thereafter. For all groups, as per protocol, animals were monitored daily for 
clinical signs of disease (hunching, ruffled fur and reduced activity) for the 
duration of the experiment. Weight loss was monitored daily for the first 
7 d, after which weight monitoring continued until the animals recovered 
to their initial starting weight or displayed weight gain continuously for 3 d. 
All mice that lost greater than 20% of their starting body weight were ground-
fed and further monitored multiple times per day as long as they were under 
the 20% cutoff. Mice that lost greater than 30% of their starting body weight 
were immediately sacrificed as per protocol. Any mouse deemed to be mori-
bund or unlikely to recover was also humanely sacrificed at the discretion 
of the researcher. Euthanasia was performed using an isoflurane overdose 
and death was confirmed by cervical dislocation. All mouse studies were 
performed at the University of North Carolina (Animal Welfare Assurance 
#A3410-01) using protocols approved by the UNC Institutional Animal Care 
and Use Committee (IACUC).
Histological analysis. The left lung was removed and submerged in 10% 
buffered formalin (Fisher) without inflation for 1 week. Tissues were embed-
ded in paraffin and 5-µm sections were prepared by the UNC Lineberger 
Comprehensive Cancer Center histopathology core facility. To determine 
the extent of antigen staining, sections were stained for viral antigen using 
a commercially available polyclonal SARS-CoV anti-nucleocapsid antibody 
(Imgenex) and scored in a blinded manner by for staining of the airway 
and parenchyma as previously described20. Images were captured using an 
Olympus BX41 microscope with an Olympus DP71 camera.
Virus neutralization assays. Plaque reduction neutralization titer assays were 
performed with previously characterized antibodies against SARS-CoV, as 
previously described11–13. Briefly, neutralizing antibodies or serum was seri-
ally diluted twofold and incubated with 100 p.f.u. of the different infectious 
clone SARS-CoV strains for 1 h at 37 °C. The virus and antibodies were then 
added to a 6-well plate with 5 × 105 Vero E6 cells/well with multiple replicates 
(n ≥ 2). After a 1-h incubation at 37 °C, cells were overlaid with 3 ml of 0.8% 
agarose in medium. Plates were incubated for 2 d at 37 °C, stained with neutral 
red for 3 h and plaques were counted. The percentage of plaque reduction 
was calculated as (1 − (no. of plaques with antibody/no. of plaques without 
antibody)) × 100.
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